Blinatumomab R&D and manufacturer

The development and production of Blinatumomab (Blinatumomab) is completed by an American biopharmaceutical company called Amgen (Amgen). AmgenFounded in 1980 and headquartered in Thousand Oaks, California (Thousand Oaks), it is one of the world's leading biopharmaceutical companies, focusing on the development and production of biological drugs, including biologics, biosimilars and genetically engineered preparations.

Belintuzumab is a bispecific antibody drug with efficacy against B cell acute lymphoblastic leukemia (B-ALL)The affinity of CD19antigen and the CD3antigen of T cells. It enhances the immune system's ability to attack leukemia cells by promoting the connection between T cells and leukemia cells. It is one of the important drugs for the treatment of B-ALL.

Amgen has extensive experience and expertise in biopharmaceuticals and is committed to developing and launching innovative treatments to meet the needs of patients with serious diseases. The successful development and production of belintuzumab is an important milestone for Amgen in the field of immunotherapy, providing a new, highly targeted treatment option for patients with B-ALL.

Amgen's scientists and research teams have exceptional expertise in the fields of biotechnology, cell engineering and antibody engineering, which enables them to develop innovative medicines such as belintuzumab. In addition, Amgen has established extensive partnerships around the world to accelerate the development and promotion of innovative medicines to improve patients' quality of life and chances of survival.

In short,Amgenas the manufacturer and developer of belintuzumab, represents advanced technology and innovation in the field of biopharmaceuticals, provides an important treatment option for patients with acute lymphoblastic leukemia, and is expected to improve the treatment effect of this disease and the quality of life of patients.